What is the recommended dosage and treatment protocol for Keppra (levetiracetam) in managing seizures?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage and Treatment Protocol for Keppra (Levetiracetam) in Managing Seizures

For managing seizures in adults, Keppra (levetiracetam) should be initiated at 1000 mg/day (500 mg twice daily) with titration up to 3000 mg/day (1500 mg twice daily) based on clinical response. 1

Adult Dosing Protocols

Partial Onset Seizures (Adults ≥16 years)

  • Initial dose: 1000 mg/day given as 500 mg twice daily 1
  • Titration: Increase by 1000 mg/day every 2 weeks 1
  • Maximum recommended dose: 3000 mg/day 1
  • Administration: Can be taken with or without food 1

Myoclonic Seizures (Adults ≥12 years with Juvenile Myoclonic Epilepsy)

  • Initial dose: 1000 mg/day given as 500 mg twice daily 1
  • Titration: Increase by 1000 mg/day every 2 weeks 1
  • Target dose: 3000 mg/day (doses lower than 3000 mg/day have not been adequately studied) 1

Primary Generalized Tonic-Clonic Seizures (Adults ≥16 years)

  • Initial dose: 1000 mg/day given as 500 mg twice daily 1
  • Titration: Increase by 1000 mg/day every 2 weeks 1
  • Target dose: 3000 mg/day 1

Pediatric Dosing Protocols

Partial Onset Seizures (Ages 4 to <16 years)

  • Initial dose: 20 mg/kg/day divided into twice daily dosing (10 mg/kg twice daily) 1
  • Titration: Increase by 20 mg/kg every 2 weeks 1
  • Target dose: 60 mg/kg/day (30 mg/kg twice daily) 1
  • Mean effective dose in clinical trials: 52 mg/kg/day 1

Primary Generalized Tonic-Clonic Seizures (Ages 6 to <16 years)

  • Initial dose: 20 mg/kg/day divided into twice daily dosing (10 mg/kg twice daily) 1
  • Titration: Increase by 20 mg/kg every 2 weeks 1
  • Target dose: 60 mg/kg/day (30 mg/kg twice daily) 1

Status Epilepticus Treatment

For status epilepticus refractory to benzodiazepines, evidence supports the following approach:

  • IV loading dose: 20-30 mg/kg 2
  • Infusion rate: 5 mg/kg/min 2
  • Efficacy: Studies show 67-73% efficacy in terminating seizures 2
  • Alternative dosing: 2,500 mg IV over 5 minutes has shown 83% efficacy in terminating seizures within 24 hours 2

Special Situations

Seizure Prophylaxis in Neurocritical Care

  • For patients with subarachnoid hemorrhage or traumatic brain injury, dosing >1000 mg/day (typically 2000 mg/day as 1000 mg twice daily) may provide better seizure prophylaxis than the standard 1000 mg/day dosing 3

Oral Loading for Rapid Initiation

  • A single 1,500 mg oral loading dose is well-tolerated and can rapidly achieve therapeutic levels 4
  • Maintenance dosing can begin 12 hours later at 500-1000 mg twice daily 4
  • This approach is useful for rapid initiation in settings like epilepsy monitoring units 4

CAR T-Cell Therapy Seizure Prophylaxis

  • For patients receiving CAR T-cell therapy with CNS disease or history of seizures: 10 mg/kg (up to maximum 500 mg per dose) every 12 hours for 30 days following infusion 2

Efficacy and Tolerability

  • Levetiracetam is effective as an adjunctive treatment for partial-onset epilepsy with or without secondary generalization 5
  • In newly diagnosed epilepsy, levetiracetam shows equivalent seizure freedom rates to controlled-release carbamazepine (73.0% vs. 72.8% at 6 months) 6
  • Most patients respond at lower doses, with 80.1% of responders achieving seizure freedom at the lowest dose level 6
  • Common adverse effects include somnolence, dizziness, infection, and asthenia 5
  • Withdrawal rates due to adverse events are approximately 14.4%, which is lower than some other antiepileptic medications 6

Important Considerations

  • Levetiracetam has minimal protein binding (10%) and minimal hepatic metabolism, reducing drug interaction potential 5
  • Dose adjustments may be necessary in patients with renal dysfunction 2
  • For patients unable to take tablets, an oral solution is available 1
  • Steady state is achieved within 2 days of twice-daily administration 5
  • Abrupt discontinuation should be avoided to prevent withdrawal seizures 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Levetiracetam.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.